From the Journals

City or country life? Genetic risk for mental illness may decide


 

FROM JAMA PSYCHIATRY

High genetic risk for a range of psychiatric illnesses appears to influence individuals’ choice of urban or rural life, new research suggests.

Individuals with a genetic predisposition to schizophrenia, bipolar disorder (BD), autism spectrum disorder (ASD), or anorexia nervosa (AN) are significantly more likely to move from a rural to an urban setting, whereas those at high genetic risk for attention-deficit/hyperactivity disorder were more likely to do the opposite.

The findings held even in those at high genetic risk who had never been diagnosed with a psychiatric disorder, highlighting a genetic factor that previous research linking urban living to mental illness has not explored.

“It’s not as simple as saying that urban environment is responsible for schizophrenia and everyone should move out of urban environments and they will be safe,” study investigator Evangelos Vassos, MD, PhD, senior clinical research fellow at King’s College London, and a consulting psychiatrist, said in an interview. “If you are genetically predisposed to schizophrenia, you will still be predisposed to schizophrenia even if you move.”

The study was published online in JAMA Psychiatry.

Genetic influence

The study results don’t rule out environmental influence, but offer evidence that the migration pattern researchers have tracked for years may have a multifactorial explanation.

“Our research shows that, at some level, an individual’s genes select their environment and that the relationship between environmental and genetic influences on mental health is interrelated,” Jessye Maxwell, MSc, lead author and a PhD candidate in psychiatry at King’s College, said in a statement. “This overlap needs to be considered when developing models to predict the risk of people developing mental health conditions in the future.”

For the study, the investigators calculated polygenic risk scores (PRS) of different psychiatric illnesses for 385,793 U.K. Biobank participants aged 37-73. PRS analyzes genetic information across a person’s entire genome, rather than by individual genes.

They used address history and U.K. census records from 1931 to 2011 to map population density over time.

PRS analyses showed significant associations with higher population density throughout adulthood, reaching highest significance between age 45 and 55 years for schizophrenia (88 people/km2; 95% confidence interval, 65-98 people/km2), BD (44 people/km2; 95%CI, 34-54 people/km2), AN (36 people/km2; 95%CI, 22-50 people/km2), and ASD (35 people/km2; 95%CI, 25-45 people/km2).

When they compared those who were born and stayed in rural or suburban areas to their counterparts who moved from those areas to cities, they found the odds of moving to urban areas ranged from 5% among people at high genetic risk for schizophrenia to 13% of those with a high risk for BD. Only people at high risk for ADHD were more likely to move to rural areas.

However, the study is not without its limitations. Only people of European descent were included, family medical history was unavailable for some participants, and only about 50,000 people had a lifetime diagnosis of mental illness, which is not representative of the general population.

‘Convincing evidence’

Still, the research adds another piece of the puzzle scientists seek to solve about where people live and mental illness risk, said Jordan DeVylder, PhD, associate professor of social work at Fordham University, New York, who commented on the study for this news organization.

Pages

Recommended Reading

Mental illness admissions: 18-44 is the age of prevalence
MDedge Internal Medicine
‘Reassuring’ findings for second-generation antipsychotics during pregnancy 
MDedge Internal Medicine
Antipsychotics tied to increased breast cancer risk
MDedge Internal Medicine
The role of probiotics in mental health
MDedge Internal Medicine
Gut health ‘vitally important’ for mental health
MDedge Internal Medicine
Antipsychotic effective for bipolar depression in phase 3 trial
MDedge Internal Medicine
COVID-19: Greater mortality among psych patients remains a mystery
MDedge Internal Medicine
Should clinicians recommend vitamin D for psychiatric patients during COVID-19?
MDedge Internal Medicine
Sleep problems in mental illness highly pervasive
MDedge Internal Medicine
FDA not recognizing efficacy of psychopharmacologic therapies
MDedge Internal Medicine